Two diabetes medications more beneficial in preventing major cardiovascular events

FHS
June 3, 2024
4:56 pm

GLP-1 receptor agonists (GLP-1s) and SGLT-2 inhibitors lower the risk of major cardiovascular events like heart attacks and severe liver complications compared to other diabetes treatments, according to data being presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.

After FDA nod, Better Therapeutics races to boost dwindling cash

You’re reading the web edition of STAT Health Tech, our guide to how tech is transforming the life sciences. Sign up to get this newsletter delivered in

July 13, 2023

Opinion | Fighting Blind: There Remains Much We Don’t Know About the H5N1 Outbreak

Adalja is a practicing infectious disease, critical care, and emergency physician. For approximately the past year, the ongoing influenza A H5N1 clade 2.3.4.4b outbreak has

August 2, 2024

AI transforms colonoscopy: Boosting detection rates, slashing miss rates in cancer screening

Researchers in China have demonstrated through a systematic review and meta-analysis that AI-based methods significantly enhance adenoma detection rates and reduce miss rates during colonoscopies,

December 4, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.